Kalaris Therapeutics is advancing its lead product candidate, TH103, a fully humanized recombinant fusion protein designed as a next-generation VEGF trap for neovascular age-related macular degeneration (nAMD). Following promising safety and initial efficacy signals from a Phase 1a single ascending dose trial, the company is now engaged in a Phase 1b/2 multiple ascending dose study aimed at optimizing dosing for potential pivotal trials. Despite the clinical progress, Kalaris faces significant financial headwinds with ongoing operating losses and the need for further capital amid complex regulatory and market dynamics. The evolving FDA pathway, intellectual property considerations, and competitive pressures characterize the critical phase of transition confronting the company.